MorphoSys (NASDAQ:MOR) Given New €37.00 Price Target at Morgan Stanley

MorphoSys (NASDAQ:MOR – Get Rating) had its price target decreased by equities research analysts at Morgan Stanley from €40.00 ($41.67) to €37.00 ($38.54) in a research report issued to clients and investors on Friday, The Fly reports. The brokerage currently has an “equal weight” rating on the stock. MOR has been the topic of a […]

Related Keywords

United States , ,Capricorn Fund Managers Ltd ,Morgan Stanley ,Berenberg Bank ,Zacks Investment Research ,Deutsche Bank Aktiengesellschaft ,Quadrant Capital Group ,Cubist Systematic Strategies ,Citigroup ,Us Bancorp ,Get Rating ,Investment Research ,Bank Aktiengesellschaft ,Capital Group ,Systematic Strategies ,Morphosys ,Nasdaq Mor ,Humor ,Medical ,Lower Price Target ,